Treatment of transthyretin cardiomyopathy with a TTR-specific antisense oligonucleotide (IONIS-TTR Rx )

Amyloid

Volumn 24, Issue , 2017, Pages 134-135

  Benson, Merrill D ^a   Ackermann, Elizabeth J ^b   Monia, Brett P ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PREALBUMIN; TRANSTHYRETIN;

ANTISENSE THERAPY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; FATIGUE; GENE MUTATION; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE WALL; HUMAN; HUMAN TISSUE; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INTERVENTRICULAR SEPTUM; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIX MINUTE WALK TEST; TREATMENT DURATION; TREATMENT OUTCOME; AMYLOID NEUROPATHY; CARDIOMYOPATHY; FAMILIAL AMYLOID POLYNEUROPATHY; GENETICS;

AMYLOID NEUROPATHIES; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PREALBUMIN;

EID: 85018751983     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506129.2017.1280015     Document Type: Letter

References (3)

1. Benson MD., Liver Transplantation and transthyretin amyloidosis. Muscle Nerve 2013;47:157–62.
2. Benson MD, Teague SD, Kovacs R, Feigenbaum H, Jung J, Kincaid JC., Rate of progression of transthyretin amyloidosis. Am J Cardiol 2011;108:285–9.
3. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW., Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006;33:609–18.